ProKidney jumps on positive mid-stage data for kidney disease drug
ReutersJul 8, 2025 12:12 PM
Shares of ProKidney PROK.O rise 62.4% to $1.25 cents premarket
Co says its drug, rilparencel, showed improvement in kidney function decline in patients with chronic kidney disease and diabetes during mid-stage trial
PROK has upcoming meeting with Food and Drug Administration to confirm approach of drug's planned late-stage trial
Up to last close, stock down 64% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Should You Buy Berkshire Hathaway Post-Warren Buffett? What's Warren Buffett's Advice for 2026 Investment?
Berkshire built up a hoard of cash through 2025, accumulating nearly $400 billion—more than it had ever held before. That was by design. Berkshire, instead of joining the artificial intelligence rally that led the headlines, put the cash into short-term U.S. Treasuries with about 3.6% yields.TradingKey
2 hours ago
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.TradingKey
14 hours ago
AMD Stock Price Prediction 2030: Can AMD Narrow Nvidia’s AI Lead?
TradingKey - In the past couple of years, the semiconductor industry has experienced a major change. One question that investors still have is whether or not AMD (AMD) will be able to keep up with Nvidia (NVDA) as far as AI is concerned. What is the possible future of AMD's stock through 2026 and beTradingKey
22 hours ago
